Grant from Northern Ireland to commercialize Onco-PDO
Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO
Press Releases
IVQ successfully grows liver cancer organoids
Invitrocue further validates its Onco-PDO technology platform through the successful growth of 14 liver cancer organoids
IVQ receives award from Singapore government IP office
IVQ receives award from Singapore government IP office
Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment
L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, …
Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs
July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of …
Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays
22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma …
Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research
February 23, 2017 – Invitrocue (ASX: IVQ) is pleased to announce that the company has signed a Collaborative Research Master Agreement with the Garvan Institute of Medical Research. The aim of the collaboration is to provide further medical validation of Invitrocue’s technology for use in personalised real time screening of cancer drugs. It is envisaged …
Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids
October 24, 2016 – Invitrocue (ASX:IVQ) announced a collaboration agreement with the Cancer Therapeutics and Stratified Oncology Group at the Genome Institute of Singapore (GIS), A*STAR. Invitrocue and GIS will jointly conduct a pilot feasibility study using Invitrocue’s cell-based 3D scaffolding technology (Onco-PDO™) to culture colorectal cancer organoids. The aim of the study is to …
InvitroCue Awarded A*STAR Tender
September 05, 2016 – InvitroCue (ASX:IVQ) has been awarded a tender by the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR), to supply and deliver Hepatocue 96-well plates and 3D-Cellusponge 96-well plates. A*STAR will be utilizing InvitroCue’s technologies to advance research on non-animal approaches to chemical safety testing under an international …
InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou
August 22, 2016 – InvitroCue Limited (ASX:IVQ) has announced that its wholly owned subsidiary InvitroCue Biomedical Service Suzhou (“InvitroCue Suzhou”) has signed a Strategic Partnership Agreement with QIAGEN Suzhou Translational Medicine Co. Limited (“QIAGEN Suzhou”). Pursuant to the agreement, InvitroCue Suzhou and QIAGEN Suzhou will jointly accelerate the discovery of biomarkers and translational medicine …